[NETosis in lupus nephritis].

To evaluate the levels of MPO-DNA complex in patients with systemic lupus erythematosus (SLE) and its association with the presence of lupus nephritis (LN). The study included 77 patients with SLE, of whom 30 had SLE without anti phospholipid syndrome (APS), 47 had SLE with APS, and 20 were healthy individuals serving as the control group. The MPO-DNA complex in the serum was investigated using ELISA. The levels of MPO-DNA complex in serum were significantly higher in patients with SLE compared to healthy controls ( Elevated levels of MPO-DNA complex were detected in 39% of patients with SLE. These patients had a higher prevalence of LN in their medical history and at the time of inclusion in the study. The correlation between MPO-DNA complex levels and the activity of LN according to SLEDAI-R indicates the potential role of MPO-DNA complex as a biomarker for assessing the activity of renal damage in SLE. Цель. Оценить уровень комплекса миелопероксидаза (МПО)-ДНК в крови у пациентов с системной красной волчанкой (СКВ) и его связь с волчаночным нефритом (ВН). Материалы и методы. В исследование включены 77 пациентов с СКВ – 30 с СКВ без антифосфолипидного синдрома, 47 с СКВ + антифосфолипидный синдром и 20 практически здоровых человек в качестве контрольной группы. Комплекс МПО-ДНК исследован в сыворотке крови методом иммуноферментного анализа. Результаты. Уровень комплекса МПО-ДНК в сыворотке крови оказался достоверно выше у больных СКВ по сравнению со здоровым контролем (